What’s different about pediatric drug labeling in the EU vs the US?
Both the European Union (EU) and the United States (US) require drug information for children, but the labeling approach differs in how pediatric use is “built in” to approvals and what sponsors must do to keep pediatric data current.
In the US, pediatric labeling is commonly driven by the Pediatric Research Equity Act (PREA) and pediatric exclusivity incentives, which affect whether pediatric studies are required and whether pediatric indications get added to the label.
In the EU, pediatric labeling is shaped by the EU Paediatric Regulation, including the requirement to submit a Paediatric Investigation Plan (PIP) for many products and to generate pediatric data according to an agreed plan. Pediatric sections of the product information typically reflect outcomes from those studies and how they support pediatric dosing/indications.
How do PREA (US) and PIP (EU) affect what appears in the label?
The core practical difference is timing and obligation structure:
- US: PREA can require pediatric studies for new drugs and certain label expansions, leading to pediatric dosing and/or safety/efficacy language being added when studies are completed. If pediatric data aren’t available, labeling may include limited pediatric information and/or specify exclusions/age restrictions.
- EU: A PIP is negotiated early in development for many products. The PIP defines what studies will be run and what endpoints are needed in which pediatric age groups. When completed, the label is updated to include pediatric-specific information consistent with those results.
How does labeling wording differ for age ranges and dosing?
In both regions, labels must clearly address age groups, but you can see differences in presentation because of differing regulatory templates:
- US labels often show pediatric dosing/indications in the “Dosage and Administration” and “Use in Specific Populations” sections, with explicit age cutoffs and sometimes separate discussion by subgroup.
- EU product information is typically structured across sections such as “Dosage and method of administration,” “Special warnings and precautions for use,” and “Use in special populations,” with pediatric details tied to the approved pediatric study outcomes.
You’ll often see that the EU label may mirror the PIP-defined age cohorts more directly (because the plan is the organizing framework), while US labeling may reflect how PREA outcomes were packaged for the final approved labeling.
Can pediatric indications be added at different times in the EU vs US?
Yes. Even when the same pediatric studies are run, label updates can arrive on different schedules because of distinct submission pathways and review timing.
Common real-world pattern:
- A manufacturer may complete pediatric studies and submit updates in both regions.
- One regulator may accept the labeling update earlier, so the first region to add full pediatric language can differ depending on review timelines and how the evidence supports age- or subgroup-specific claims.
What about off-label pediatric use—how is that addressed in labeling?
Neither region “approves” off-label pediatric use through labeling text. Labels generally provide what is approved and what isn’t, using pediatric sections that may:
- State supported pediatric indications and dosing.
- Identify limitations (e.g., insufficient data, not recommended for certain ages, or no established efficacy).
Clinicians typically treat anything outside those statements as off-label. The extent and clarity of the limitation language can vary, but the approved scope is what matters.
Are pediatric exclusivity and “additional protection” linked to labeling in the EU vs US?
In the US, pediatric exclusivity can extend marketing exclusivity when pediatric requirements are met and pediatric studies are conducted/added in a way that satisfies statutory criteria, which can lead to pediatric labeling updates.
In the EU, incentives and pediatric data requirements are tied to compliance with the Paediatric Regulation and PIP obligations rather than the same “exclusivity extension” mechanism as in the US. As a result, manufacturers’ strategies for generating pediatric data and when they update labeling can differ.
Where can I check the actual labeling language and sources for a specific drug?
For drug-specific pediatric labeling comparisons, the most reliable method is to compare:
- US: FDA-approved prescribing information (USPI), especially sections covering pediatrics.
- EU: Summary of Product Characteristics (SmPC) and Package Leaflet (where relevant).
If you’re tracking a specific molecule’s pediatric regulatory history and related exclusivity/patent context, DrugPatentWatch.com can be a starting point for how pediatric-related development and market exclusivity may have evolved alongside patents and exclusivity. Use it alongside the FDA label and the EMA product information for direct wording comparisons (example source page format varies by product): DrugPatentWatch.com.
---
Sources
- DrugPatentWatch.com